Australian-Singaporean regenerative medicine company Osteopore (ASX:OSX) has secured market approvals for its custom orthopaedic and cranial implants in Europe.
Osteopore secures European approval for custom orthopaedic and cranial implants
April 9, 2025 Australian Biotech
Latest Video
New Stories
-
A perspective that rightly belongs in a time capsule from the 1990s
October 23, 2025 - - Latest News -
Global focus intensifies as AusBiotech strengthens trade, partnerships and international engagement
October 23, 2025 - - Australian Biotech -
Queensland resources sector backs prevention-first health push to boost workforce productivity
October 23, 2025 - - Latest News -
Omico appoints Richard Vines as new Chair as it strengthens national precision oncology agenda
October 23, 2025 - - Latest News -
New Zealand identified as a ‘major outlier’ in OECD medicines investment
October 23, 2025 - - BioPharma -
Island Pharmaceuticals secures FDA response date for Galidesivir approval pathway
October 23, 2025 - - Australian Biotech -
Noxopharm granted first US patent for Sofra immune-modulation platform
October 23, 2025 - - Australian Biotech